READYCURE, which is developing a digital X-ray-based dementia treatment system, announced on the 25th that it has signed a business agreement (MOU) with CUREVERSE, a brain disease treatment development company, for the 'development of a digital X-ray-based brain drug delivery optimization system.'
This agreement aims to jointly develop a new platform for treating intractable brain diseases by combining digital X-ray technology and new drug development capabilities. The agreement was signed on the 18th, and the two companies plan to jointly research drug delivery optimization technology for controlling the blood-brain barrier (BBB) and restoring the brain environment.
Redicure is developing a technology that uses the biological action mechanism of digital X-rays to increase drug absorption rates and therapeutic efficacy, and in this project, it is in charge of optimizing X-ray conditions and analyzing the action mechanism. Cureverse plans to apply its brain disease treatment new drug candidate 'CV-01' to the digital X-ray platform to verify its efficacy and promote clinical phase expansion.
CV-01 is a small molecule new drug targeting the keap/Nrf2 pathway, and is currently undergoing phase 1 clinical trials at Seoul National University Hospital. In 2024, Curebus signed a technology transfer agreement worth approximately KRW 500 billion with Italian pharmaceutical company Angelini Pharma, securing a foundation for entering the global market.
Redicure is developing a digital dementia treatment system called 'HeLaXON' based on low-dose, low-energy X-ray technology based on carbon nanotubes, and is accelerating the advancement of its technology after being selected for the 2024 Ministry of SMEs and Startups' Deep Tech TIPS project. The system has proven to improve cognitive function and reduce amyloid accumulation in large-scale clinical trials targeting early-stage Alzheimer's patients based on multi-mechanism actions such as anti-inflammation, neuroprotection, and protein removal.
“This collaboration is the starting point for the development of a platform that can maximize therapeutic effects through the fusion of medical devices and new drugs,” said Redicure CEO Jeongwon Gyu. “Digital X-ray technology may receive attention as a new mechanism for enhancing the efficacy of new drugs.”
Curebus CEO Jo Seong-jin also said, “We expect that through the synergy between digital X-ray-based technology and new drug candidates, we will be able to present new treatment options for intractable brain diseases.”
- See more related articles
You must be logged in to post a comment.